CUMULATIVE INDEX 1994

Volume 12

March	NEW DRUGS IN ANESTHESIA: PART II, pages 1–172
June	CLINICAL ISSUES IN MONITORING, pages 173–386
September	TEMPERATURE REGULATION DURING ANESTHESIA, pages 387–634
December	ORGAN TRANSPLANTATION, pages 635–868

Note: Page numbers of issues and article titles are in **boldface** type.

α_2-adrenergic agonists, **49–63**
  dose-response relationship, 55
  pharmacologic and physicochemical properties, 51–62
    analgesia, 59–60
    clinical uses, 60–62
      premedication, 60–62
    heart rate and rhythm, 55, 56
    hemodynamic effects, 53–55
    hormonal effects, 58, 59
    respiration, 57, 58
    sedation/anesthesia, 56, 57
  receptor classification, 49–51
β-adrenergic receptor kinase, 5
β-adrenergic receptors, 2
  in other organs and conditions, 11, 12
Ability to monitor, 345–353
  environmental factors, 350, 351
    environmental toxicity, 351
    lighting, 350
    noise, 350
    temperature, 350
  equipment factors, 351–353
    alarms, 352, 353
    automation, 353
    ergonomics, 351, 352
    familiarity with equipment, 352
  human factors, 345–349
    boredom, 345, 346
    experience, 349
    fatigue, 345, 346
    interpersonal dynamics, 348
    personal stressors, 348, 349
    sleep deprivation, 346, 347
    sleep disturbance, 346, 347
    substance abuse, 347, 348
    substance use, 347, 348
    team dynamics, 348
    training, 349
    workload, 347
Acetylsalicylic acid, 216
Acquired immunodeficiency virus. See *AIDS.*
ACT. See *Activated clotting time.*
Activated clotting time, 221, 227, 232
Acute tubular necrosis, 719
Adenosine. See *Cardiac pharmacology, inotropic treatment, with inodilators.*
Adrenergic drugs, selectivity of, 50
Adult respiratory distress syndrome, 718, 724, 809, 812, 817, 818
Advances in antiemetic therapy, **119–132.** See also *Antiemetic therapy, advances in.*
AEP. See *Evoked potentials, auditory.*
AIDS, 657
Alfentanil, 699
ALG. See *Antilymphocyte globulin.*
Aminocaproic acid. See *Antifibrinolytic compounds.*
Analgesic concentration, minimum effective, 66
Anesthesia. See *Nonconventional drug administration in anesthesia.*
Anesthesia and liver transplantation, **717–727**
Anesthesia database, **371–381**
  electronic patient chart, 379
  history, 372–374
  national anesthetic database, 378, 379
  power of, 379, 380
  volume of data, 371

Anesthesia for heart and heart-lung transplantation, **729–747**
Anesthesia for renal transplantation, **691–715**
Anesthesia monitoring equipment, 357–368
Anesthetic considerations for the previously transplanted patient, **827–843**
Anesthetic considerations of the burn patient, **789–805**
Anesthetic gas analysis, 330
Angiotensin-converting enzyme, 8
Antiemetic therapy, advances in, 119–132
Antifibrinolytic compounds, 98–103
  aminocaproic acid, 101–103
  chemistry of, 98–100
  mechanism of action, 100, 101
Antilymphocyte globulin, 819, 820, 821, 834, 838
Antithymocyte globulin, 735, 820, 821
Aprotinin, 106–108, 725
  adverse effects, 108
  for cardiac surgery, 107
  for non-cardiac surgery, 106
βAR. See *β-adrenergic receptor.*
ARDS. See *Adult respiratory distress syndrome.*
Arterial blood gas analysis, 312, 313
  interpretation of data, 312, 313
  temperature correction of data, 313
Arterial cannulation, 199
ATG. See *Antithymocyte globulin.*
Athrogryposis, 485
Athrogryposis multiplex congenita, 485, 486
Atracurium, 702, 703. See also *Mivacurium versus atracurium.*
Auditory steady-state response, 186
Azathioprine, 735, 819, 820, 834, 837, 838

Bacteremia and sepsis, 476–477
Beer's law, 263, 264, 272
Blood pressure measurement, 293–297
  arterial, 296, 297
  central venous, 297
  invasive techniques, 295
  noninvasive techniques, 293–295
  pulmonary artery, 297
Body temperature, core, 393, 394, 396–403, 419, 426–442, 446–448, 465, 528, 539
  peripheral, 393, 397, 400–402
Body temperature monitoring, **387–407**
  equipment, 390–393
    infrared thermometer, 393, 394
    liquid crystal thermometer, 392, 393
    mercury in glass thermometer, 390, 391
    thermistors, 391, 392
    thermocouples, 391
  guidelines, 399–401
    cardiac surgery, 400, 401
    pediatric surgery, 399, 400
  history, 387, 388
    first thermometer, 388
  sites, 393–398
    esophagus, 395, 396
    mouth, 398
    nasopharynx, 396
    rectum, 396, 397
    skin surface, 397, 398
    tympanic membrane, 394, 395
    urinary bladder, 397
Brain death, 643–653
  ancillary tests for, 649
  criteria for, 644–649
  current controversies, 651, 652
  declaration of, 643–653
  guidelines for, 648
  Harvard criteria, 644
  historical perspective, 643–646
  legal perspective, 646, 647
Bronchopulmonary dysplasia, 288
Buprenorphine. See *Nonconventional drug administration in anesthesia.*
  intravenous versus intranasal, 24
Burn patients, 789–802
  anesthesia for, 789–802
  anesthetic management of, 797–801
    blood loss and transfusion, 800
    induction and maintenance, 798, 799
    other considerations, 800, 801
    preoperative evaluation, 797, 798
  initial management of, 796, 797
    airway/respiratory management, 796
    associated injuries, 797
    evaluation of fluid/volume status, 796, 797
  pain relief, 801
  pathophysiology of, 790–793
    airway/respiratory derangements, 790, 791
    cardiovascular/hematologic derangements, 792
    circumferential chest burn, 791–792
    hepatic system derangements, 793
    metabolic and nutritional derangements, 792, 793
    renal system derangements, 793
  pharmacology of, 794–796
    adrenergic agents, 795, 796
    analgesics, 795
    anesthetics, 795
    anxiolytics, 795
    muscle relaxants, 794, 795
  postoperative care, 801
Burns of the chest, 791
Burprenorphine. See *Opioids, agonist-antagonists.*

Butorphanol. See *Nonconventional drug administration in anesthesia.*

Capnography, 265, 273, 288, 289, 291, 292
  accuracy of, 288–292
Carbon dioxide measurement, 264–268
  electrochemical sensors, 264, 265
  photochemical sensors, 265
  respiratory, 265, 266
    capnography, 265
    infrared absorption spectrometry, 266
    mass spectrometry, 265, 266
    Raman spectrometry, 266
Cardiac adrenergic receptors, 7–9
Cardiac failure, in children, 780
Cardiac pharmacology, inotropic treatment, 134–163
  with inodilators, 135–162
    adenosine, 156–162
    dopexamine, 142–148
    Enalaprilat, 148–156
    milrinone, 135–142
  with sympathomimetics, 135–142
  recent advances in, 133–168
Cardiac surgery. See *Aprotinin; Desmopressin; Tranexamic acid.*
Cardiopulmonary bypass, 173, 178, 220–222, 225–228, 231, 548, 666, 673, 674, 682–687, 749, 757–759, 763, 809, 810
CBF. See *Cerebral blood flow.*
Cefuroxime, 734
Central diabetes insipidus, 668
Central nervous system, 173–190
Central nervous system dysfunction, 481, 482
Central temperature. See *Body temperature, core.*
Centrifugal pumps, 674–676
Cerebral blood flow, 187, 188
Cerebral blood flow measurement, 650
Clark electrode, 261, 262
Clinical controversies in malignant hyperthermia susceptibility, **537–551**
CMAP. See *Compound muscle action potential.*
CMV. See *Cytomegalovirus.*
CNS. See *Central nervous system.*
CO_2 measurement. See *Carbon dioxide measurement.*
CO_2 optodes, 265
Coagulation proteins, 213
Coagulation system, 211–232
Compound muscle action potential, 183, 184
Consent for donation, 638–641
  requesting, 640, 641
  types of, 639, 640
Consequences and treatment of perioperative hypothermia, **425–456**
Context-sensitive half-time, 66–68
Core temperature. See *Body temperature, core.*
Corticosteroids, 818
Cost of monitoring, 323–340
Cost of monitors, 339, 340
CPB. See *Cardiopulmonary bypass.*
Critical care management, 807–824
Current laboratory methods for the diagnosis of malignant hyperthermia susceptibility, **553–570**
Cyclosporine, 735, 761, 813, 818–820, 833–836
Cytomegalovirus, 657, 685, 732, 734, 739, 740, 754, 760–762, 823, 828, 829

D-Tubocurarine, 701
Database of the future, 376–378
  intraoperative data, 376, 377
  postoperative data, 377
  preoperative data, 377, 378
Declaration of brain death, **643–654**
Deep hypothermic circulatory arrest, 461–469
  anesthetic management, 463, 464
  history, 461, 462
  indications, 462, 463
  metabolic and hormonal response, 466
  neurologic sequelae, 467–469
    cerebral dysfunction, 467, 468
    choreoathetosis, 468, 469
    transient seizure activity, 468
  pH stat versus alpha stat, 466, 467
  technique, 464–466
Desensitization, 4
Desflurane versus isoflurane, 44, 45
Desmopressin, 91–98
  for cardiac surgery, 95, 96
  complications of, 96–98
  for hemophilia and von Willebrand's disease, 93, 94
  for liver cirrhosis, 94
  for non-cardiac surgery, 95
  physiology and pharmacology of, 91–93
  for prolonged bleeding, 94, 95
  for uremia, 94
DHCA. See *Deep hypothermic circulatory arrest.*
Diabetes, 668
Diatek Arkive database, 372, 375, 376
  artifact, 372, 375
  clinical practice, 375
  hospital billing, 375, 376
Diazepam, 720
DIC. See *Disseminated intravascular coagulation.*

Differential diagnosis of hyperthermia during anesthesia and clinical import, **475–489**
DINAMAP, 202, 203
Direct invasive arterial monitoring, 197–200
Disseminated intravascular coagulation, 219, 230, 231
Distal sampling, 289–292
Donors. See *Organ donors.*
Dopexamine. See *Cardiac pharmacology, inotropic treatment, with inodilators.*

ECMO. See *Extracorporeal membrane oxygenation.*
Economic considerations for new anesthesia drugs, **39–48**
EEG. See *Electroencephalography.*
Electrocardiography, 325, 326
Electroconvulsive therapy, 506
Electroencephalography, 173–179
  analysis, 175
  cardiac surgery, 178, 179
  cerebral ischemia monitoring, 178
  computerized monitoring, 175, 176
    compressed spectral array, 176
    density-modulated spectral array, 176
    epoch, 176
    power spectrum, 176
  depth of anesthesia, 177, 178
Enalaprilat. See *Cardiac pharmacology, inotropic treatment, with inodilators.*
Endplate potential, 237
Enflurane, 186, 704
EP. See *Evoked potentials.*
Essentials of organ donor problems and their management, **655–671**
Ethics and future trends in transplantation, **845–855**
Etomidate, 184, 733
Evoked potentials, 173, 179–186
  acquisition, 179, 180
  auditory, 185, 186
    brain stem, 185, 186
    middle latency, 186
  clinical application, 182, 183
    carotid endarterectomy, 182, 183
    spinal surgery, 182
    thoracic aortic surgery, 182
  motor, 183–185
    clinical experience with monitoring, 185
    effects of anesthetics, 184, 185
    neurogenic, 183, 185
    sensitivity to spinal cord injury, 183, 184
    techniques for improving amplitude, 185
  somatosensory, 180–182
    anesthetic techniques, 180–182
Extracorporeal membrane oxygenation, 676, 680

Faraday cage, 299
FDP. See *Fibrin degradation products.*
Febrile nonhemolytic reactions, 483
Fentanyl, 184, 682, 699, 720, 733, 756. See also *Nonconventional drug administration in anesthesia.*
  intravenous versus intranasal, 22
  pharmacokinetic data, 67
Fentanyl citrate, oral transmucosal, 25–29
  analgesia, 28, 29
  preoperative sedation, 26–28
  US Food and Drug Administration approval of, 29
Fibrin degradation products, 219–221, 223
Fibrinogen, 219–221
  activated coagulation time, 220, 221
  reptilase time, 219, 220
  thrombin time, 219, 220
Fibrinolysis, tests of, 221
FK506, 834, 838, 839
Fluorescence quenching, 263
Functional residual capacity, 718

G-protein. See *Guanine-nucleotide protein.*
G-protein–linked receptors, 2–4
  regulation of other, 12, 13
G-proteins, 2–4
Galileo, 387, 388
Gallamine, 700
Genetic counseling, 599–605
Genetic counseling by the anesthesiologist, **599–606**
Genetic disorders, features of, 599, 600
Guanine-nucleotide binding protein, 2

Halothane, 554–561, 704, 705, 720
Health-care expenditures, 39
Heart failure, 780
Heart-lung transplantation, 729–744, 810, 811
  anesthesia, 742, 743
  donor selection, 739, 740
  indications for, 738, 739
  postoperative management, 743, 744
  preoperative evaluation, 732
  recipient assessment, 739
  recipient selection, 738, 739
  surgical procedure, 740–742
    donor, 740, 741

recipient, 741, 742
Heart transplantation, 729–744, 777, 779–782, 807–809
anesthesia, 732–737
induction and bypass, 733–735
monitoring, 733
preoperative assessment, 732, 733
donor selection, 731, 732
epidemiology, 730
immunosuppression, 735
indications for, 730, 731
infection prophylaxis, 734
postoperative care, 735–737
recipient selection, 730, 731
surgical procedure, 734, 735
Heat stroke, 499, 539, 540
Hemodynamic data, 659
Hemophilia. See *Desmopressin.*
Hemostasis, 211–232
bleeding time, 215–226
fibrinolytic therapy, 231
history of, 212–214
intraoperative blood salvage, 229, 230
intraoperative coagulation factor, 230, 231
monitoring in special intraoperative situations, 226–229
cardiopulmonary bypass, 226–228
massive blood loss, 228, 229
phases of, 212
plasma therapy, 230, 231
platelet count, 215–226
platelet function, 215–226
preoperative tests, 214, 215
therapeutic intervention for special abnormalities, 231
Hemostatic therapy, **91–117**
Heparin, 771
Hepatic failure, 773, 774
Hepatitis, 657, 732
Herpes simplex virus, 657, 732, 761, 762, 823
HIV, 657, 732
Human erythropoietin, 109
Human immunodeficiency virus. See *HIV.*
Hyperkalemia, 701
Hyperthermia, intraoperative, causes of, 475–487
blood transfusion reactions, 482–484
disease states, 476–482
genetic causes, 484–486
iatrogenic causes, 484
Hyperthermia and neuroleptic malignant syndrome, **491–512**
Hypotension, 657–668
Hypothermia, inadvertant, 389, 390
intentional, 389
intraoperative, prevention and treatment, 438–449
airway heating and humidification, 441–443
cutaneous warming, 443–447
heat redistribution, 439–441
intravenous fluids, 443
intraoperative consequences, 425–430
cerebral ischemia, 426
coagulation, 428–430
clotting factor enzyme function, 429
fibrinolysis, 429, 430
platelet function, 429
hypoxia, 426
pharmacokinetics and dynamics, 427, 428
intravenous anesthetics, 428
muscle relaxants, 427, 428
volatile anesthetics, 427
perioperative, 413–417, 425–449
physiologic modifications, 413–417
internal redistribution of heat, 414, 415
thermal imbalance, 415–417
thermoregulation responses, 417
postoperative consequences, 430–438
discomfort, 436, 437
hemodynamic effects, 432, 433
myocardial ischemia, 432, 433
postanesthetic shivering, 433, 434
prolonged recovery, 434–436
respiratory dysfunction, 434–436
return to normothermia, 430–432
surgical wound infections, 437, 438
Hypothermia during anesthesia, **409–424**
Hypothermia for cardiac surgery and circulatory arrest, **457–474**
Hypothermic cardiopulmonary bypass, 457–461
cerebral protectants, 458, 459
hypothermia and perfusion pressure, 459–461
myocardial and cerebral protection, 457, 458

ICU. See *Intensive care unit.*
IMM 125, 834, 839
Immunosuppression, 818–821
antilymphocyte globulin, 820, 821
antithymocyte globulin, 820, 821
azathioprine, 820
corticosteroids, 818
cyclosporine, 818–820
OKT3, 821
preference of, 821
IND. See *Pharmaceuticals, investigational new drug application.*
Indirect noninvasive pressure monitoring, 200–207
auscultation, 201
noninvasive and non-occlusive, 205–207
arterial tonometry, 206, 207

Indirect noninvasive pressure monitoring *(Continued)*
Penaz method, 205–207
occlusive pulse systems, 204, 205
oscillometry, 201–203
peripheral pulse detection, 203, 204
Infection versus rejection, 821–824
heart-lung transplantation, 822, 823
heart transplantation, 822
liver transplantation, 823, 824
lung transplantation, 822
Inotrope requirements, 663
Intensive care unit, 307–319, 323, 328, 334, 336, 636–638, 649, 650, 755, 807–824
organization of monitoring, 307, 308
technology, 307, 308
Intra-arterial catheters, 333, 334
Invasive oxygen monitoring, 270–273
PO_2 electrode, 270–273
PO_2 optode, 270–273
Isoflurane, 705, 720, 756, 757. See also *Desflurane versus isoflurane.*
Isoproterenol, 781
Ivy bleeding time, 213

Ketamine, 733. See also *Nonconventional drug administration in anesthesia.*
Kidney failure, 768, 769
Kidney transplantation, 691–708, 767–772, 814

Lee-White whole blood clotting time, 220, 221
Left ventricular assist systems, 678, 686, 687
Liver cirrhosis. See *Desmopressin.*
Liver disease, end-stage, 717, 718
Liver failure, 773, 774
Liver transplantation, 717–725, 772–778, 811–814
anesthesia and, 717–725
cardiovascular status, 718, 719
hematologic status, 719
induction and maintenance, 720, 721
intraoperative monitoring, 720
metabolic status, 719
neurologic status, 717, 718
nutritional status, 720
perioperative implications, 717
premedication, 720
preoperative assessment, 717
renal status, 719
respiratory status, 718
controlling bleeding during, 724, 725
significant events during, 721
surgical procedure, 721–724
anhepatic stage, 722, 723
intraoperative use of OKT3, 723, 724
postoperative care, 723
preanhepatic stage, 721, 722
reperfusion/neohepatic stage, 723
Lorazepam, 682, 720
Luminescence lifetime, 263
Lung transplantation, **749–765**, 782–786, 809, 810
donor management, 753, 754
history of, 749, 752
indications for, 753
intraoperative anesthesia, 755–759
induction and maintenance, 756, 757
operating room preparation, 755, 756
intraoperative problems, 757–759
alveolar-arterial oxygen gradient, 757
cardiopulmonary bypass, 758, 759
end-tidal carbon dioxide, 757
hypothermia, 758
inadequate one-lung ventilation, 757, 758
mortality, 761–763
outcome, 762
postsurgical management, 759–762
antimicrobial therapy, 760, 761
hemodynamic management, 760
nutrition, 760
rejection, 761
ventilation, 759, 760
preoperative anesthesia, 754, 755
recipient selection, 752
surgical procedure, 759
Lymphocyte cyclic adenosine monophosphate production, 11

MAC. See *Minimum alveolar concentration.*
Magnetic resonance imaging, 286, 299–301
Malignant hyperthermia, 388, 389, 425, 426, 427, 475, 478–482, 484–487, 491, 499–508, 513–532, 537–548, 553–566, 571–605, 599–605, 607–619, 621–626
anesthesia for, 521–525
agents, 521, 522
anesthesia machine, 525
dantrolene prophylaxis, 522–524
postoperative management, 524, 525
associated neuromuscular disorders, 515–517
carnitine palmitoyl transferase deficiency, 516
central core disease, 515, 516
Duchenne muscular dystrophy, 516, 517
King syndrome, 516
cardiopulmonary bypass surgery, 548
creatinine kinase testing, 515
dantrolene prophylaxis, 522–524, 546

diagnostic testing, 553–566
blood tests, 562–564
clinical guidelines, 564–566
contracture tests, 554–566
alternatives to, 561–564
halothane and caffeine contracture tests, 554–561
effects of drugs on outcome, 560, 561
muscle biopsy, 554, 555
sensitivity and specificity, 559, 560
standard protocols, 556–559
tissue bath, 555
nuclear magnetic resonance scanning, 561, 562
in vitro contracture test, 554, 556
global issues, 625, 626
intraoperative diagnosis, 517–521
clinical presentation, 519–521
pathophysiology, 517–519
masseter muscle rigidity, 542–545
mortality, 530, 531
occurrence without anesthesia, 538–541
preoperative diagnosis, 513–515
registry, 607–619
patient reports, 609–612
patients, 612
reporting forms, 608, 609
research projects, 612–619
susceptibility, 537–548, 553–566, 571–605, 599–605
animal models, 580
causal mutation, 589
developments in genetics, 590, 591
genetic counseling, 600–605
identifying candidate genes, 579–582, 583–586, 586–589
linkage analysis, 586, 587
markers and mutations, 591, 592
molecular genetic techniques, 572–575
monogenic disorders, 577–579
multiple congenital anomalies, 575–577
multiple gene involvement, 590
nongenetic, 591
restriction fragment length polymorphisms, 582, 583
risk assessment, 602, 603
special problems, 600, 601
treatment, 526–531
after acute episode, 529, 530
changes in therapy, 528, 529
dantrolene therapy, 528
emergency therapy, 527
temperature control, 526–528
ventilation, 526
wakeful episodes, 547, 548
Malignant Hyperthermia Association of the United States, 526, 530, 601, 604, 621–629
funding, 623, 624
hotline, 624, 625
mission, 622, 623
publications available, 627
Malignant Hyperthermia Association of the United States and other malignant hyperthermia organizations, **621–629**
Malignant hyperthermia associations, 538, 558, 604, 607–619, 621–629
outside the United States, 538, 556, 591, 624
Malignant hyperthermia susceptibility, **513–535**
Management of the transplant patient in the intensive care unit, **807–826**
Mannitol, 707, 708
MAP. See *Muscle action potential.*
MEAC. See *Analgesic concentration, minimum effective.*
Mechanical devices, **673–689**
centrifugal pump, 674–676
description of, 674–679
historical aspects, 674
ventricular assist device, 674–679
Mechanical ventilation, weaning from, 815–818
heart-lung transplantation, 817
heart transplantation, 816
liver transplantation, 817, 818
lung transplantation, 816, 817
MEP. See *Evoked potentials, motor.*
Meperidine, 698
Meptazinol. See *Opioids, agonist-antagonists.*
Methoxyflurane, 704
Methylprednisolone, 735, 761, 771, 819
Metocurine, 682
MH. See *Malignant hyperthermia.*
MHAUS. See *Malignant Hyperthermia Association of the United States.*
MHS. See *Malignant hyperthermia, susceptibility.*
Midazolam, 184, 682, 720, 733, 757, 769. See also *Nonconventional drug administration in anesthesia.*
intravenous versus intranasal, 20
Milrinone. See *Cardiac pharmacology, inotropic treatment, with inodilators.*
Minimum alveolar concentration, 389, 418, 426
Minimum effective analgesic concentration. See *Analgesic concentration, minimum effective.*
Mirfentanil. See *Opioids, new and investigational.*
Mivacurium, 703
Mivacurium versus atracurium, 45, 46
Monitoring in the intensive care unit, **307–321**
new measuring devices, statistical comparison of, 316, 317
recent advances, 315–317

Monitoring in the intensive care unit *(Continued)*
continuous intravascular blood gas, 315
noninvasive cardiac output measurement, 315, 316
Doppler ultrasound, 316
thoracic electical impedance, 315, 316
Monitoring neuromuscular block, **237–260**
Monitoring technology, economics of, 317, 318
health care, 318
introducing, 317, 318
Monitoring the central nervous system, **173–196**
Monitoring the coagulation system, **211–236**
Monitoring the pediatric patient, clinical observation, 277–280
circulation, 279, 280
depth of anesthesia, 280
oxygenation, 278
temperature, 280
ventilation, 278, 279
extended, 280–293
capnography, 288
circulation, 292
electrocardiogram, 292
expired tidal volume, 287, 288
inflation pressure, 287
interference, 284–286
oxygenation, 281, 282
pulse oximetry, 282, 283
response time, 283, 284
sensor placement, 283
transcutaneous oxygen, 286
ventilation, 287
special considerations, during MR imaging, 299, 300
sedated outpatient, 298, 299
Monitoring the pediatric patient, special considerations and issues, **277–306**
Monitoring the peripheral vascular system, **197–209**
Morphine, 698. See also *Nonconventional drug administration in anesthesia.*
MR imaging. See *Magnetic resonance imaging.*
Muscle action potential, 237, 238, 245, 247, 248

Nalmefene. See *Opioid antagonists, newer.*
Nalorphine-like compounds. See *Opioids, agonist-antagonists.*
Naloxone. See *Nonconventional drug administration in anesthesia.*
Naltrexone. See *Opioid antagonists, newer.*
Narcotic agonists and antagonists, **65–89**
NDA. See *Pharmaceuticals, new drug application.*
Near-infrared transcranial spectroscopy, 188–190
Neuroleptic malignant syndrome, 491–508
associated disorders, 497–500
primary brain disorders, 498
infections, 498
lethal catatonia, 498
structural lesions, 498
systemic disorders, 498–500
autoimmune disorders, 499
endocrinopathies, 499
heat stroke, 499
infections, 498, 499
toxins and drugs, 499
clinical manifestations, 492–497
clinical pharmacology, 493, 494
incidence, 492
risk factors, 492, 493
signs and symptoms, 494–497
implications for management, 506, 507
anesthesia, 507
pharmacotherapy, 506
prevention, 506
psychiatry, 506, 507
and malignant hyperthermia, 501–506
animal data, 502, 503
clinical data, 501, 502
in vitro contracture studies, 503–506
Neurologic function monitoring, 331, 332
Neuromuscular block, 237–255
maintenance, 253
onset, 252, 253
readiness for extubation, 254, 255
recovery, 253, 254
Neuromuscular junction, 237, 238
Neuromuscular monitoring, 239–252
assessment of evoked responses, 247–249
accelerography, 249
adductor pollicis force translation monitor, 248
compound muscle action potential, 247
electromyogram, 247
evoked contractile response, 247, 248
preload, 249
features of neurostimulation, 239–241
current intensity, 240
impedance, 240
needle electrodes, 240
nerve stimulator, 239
pulse width, 240
stimulus frequency, 241
stimulus strength, 240
submaximal current, 240
supramaximal current, 240
surface electrodes, 240, 241

threshold current, 240
monitoring sites, 249–252
abductor digiti quinti, 250, 251
adductor pollicis, 249–251
facial nerve, 251, 252
first dorsal interosseous, 250, 251
nerves of the foot, 251
respiratory muscles, 252
ulnar nerve, 249, 250
patterns of neurostimulation, double burst stimulation, 246, 247
posttetanic count, 246
posttetanic stimulation, 245, 246
single twitch, 241, 242
tetanic stimulation, 244, 245
train-of-four, 242–244
Neuromuscular transmission, 237–239
channel block, 239
depolarizing block, 238, 239
nondepolarizing block, 238
normal, 237, 238
Neuromuscular transmission monitoring, 331
Nicotinic cholinergic receptors, 13
NMS. See *Neuroleptic malignant syndrome.*
Non-cardiac surgery. See *Aprotinin; Desmopressin; Tranexamic acid.*
Nonconventional drug administration in anesthesia, **17–38**
intranasal, buprenorphine, 23
butorphanol, 23
fentanyl, 22, 23
ketamine, 23, 24
midazolam, 19, 20
naloxone, 24
sufentanil, 21, 22
oral mucosal, 24–34
buccal, 25–31
fentanyl citrate, 25–29
morphine, 29–31
sublingual, 31–34
buprenorphine, 32, 33
lorazepam, 31, 32
midazolam, 31
morphine, 34
Nondepolarizing relaxants, 238, 242
Noninvasive blood pressure monitoring, 324, 325
Noninvasive oxygen monitoring, 268–270
PO_2, 268, 269
conjunctival, 268, 269
transcutaneous, 268
SO_2, 269, 270
SpO_2, 269, 270
tissue oximetry (StO_2), 270
Noninvasive presymptomatic diagnosis of malignant hyperthermia susceptibility using molecular genetic techniques, prospects for, **571–597**
Nonsteroidal anti-inflammatory drugs, 216
Normothermic cardiopulmonary bypass, 461
North American Malignant Hyperthermia Registry, **607–620**

O_2 measurement. See *Oxygen measurement.*
Odansetron, 126–130
OKT3, 717, 723, 724, 819, 823, 834, 837, 838
OLT. See *Orthotopic liver transplantation.*
Opiates, 697, 698
Opioid administration, newer methods of, 69–75
central neuraxial, 70–72
computer-assisted continuous infusion, 69–70
intranasal, 73, 74
transdermal, 72, 73
transmucosal, 74, 75
pharmacokinetics and pharmacodynamics of, 65–69
Opioid antagonists, newer, 82–84
nalmefene, 82, 83
naltrexone, 83, 84
Opioids, agonist-antagonists, 78–82
burprenorphine, 80, 81
epidural administration of partial, 82
meptazinol, 81
nalorphine-like compounds, 79, 80
new and investigational, 76–78
mirfentanil (A 3508), 77, 78
rapifentanil (A3331), 77
remifentanil (GI87084B), 76, 77
Organ donation, **635–642**
consent for, 638–641
process, 636, 637
rates, 639
resource requirements, 637, 638
hospital policy, 637
personnel, 637, 638
space and facilities, 638
Organ donor death, causes of, 657
Organ donor identification, 656, 657
Organ donor problems, 657–665
arrhythmias, 664, 667
central diabetes insipidus, 664–667
hypotension, 657–664
hypothermia, 665
respiratory, 665, 667
treatment of, 665–668
Organ donor procurement, 667, 668
Organ donors, 655–668
cadaveric, 639
Organ function, evaluation of, 807–815
heart-lung transplantation, 810, 811
heart transplantation, 807–809
kidney transplantation, 814
liver transplantation, 811–814
lung transplantation, 809, 810

Organ function *(Continued)*
pancreas transplantation, 814, 815
Organ recipients, survival of, 636
Orthotopic liver transplantation, 724, 725
Osteogenesis imperfecta, 484, 485
OTFC. See *Fentanyl citrate, oral transmucosal.*
Oxygen measurement, 261–264
electrochemical sensors, 261, 262
hemoglobin saturation, 263, 264
photochemical sensors, 262, 263

Pancreas transplantation, 814, 815
Pancuronium, 682, 701, 702, 721, 756
Partial thromboplastin time, 213, 214, 217–219, 228
PCO_2 optode, 274
Pediatric patients, 277–301. See also *Monitoring the pediatric patient.*
Pediatric transplantation, 767–786
cardiac, 777, 779–782
anesthetic management, 780–782
surgical technique, 780
hepatic, 772–778
anesthetic management, 775–777
problems during, 777
surgical technique, 774, 775
lung, 782–786
anesthetic management, 783, 784, 786
surgical technique, 783
renal, 767–772
anesthetic management, 769–772
surgical technique, 769, 770
Perioperative adrenergic receptors, 9–11
Peripheral temperature. See *Body temperature, peripheral.*
Peripheral vascular system, 197–207
Pharmaceuticals, approval of new drugs, 42, 43
clinical trials, 42
development and approval process, 41
development of, 40–43
investigational new drug application, 42
new drug application, 42
Pharmacologic response, impact of receptor regulation, 1–16
Pheochromocytoma, 480, 481
PKA. See *Protein kinase*
Platelet factor 4, 108, 109
PO_2 optode, 262, 263
Posttetanic count, 246, 253
Posttetanic facilitation, 239, 245, 246, 253
Prednisone, 735, 819
Previously transplanted organs, 829–839
anesthetic considerations, 829–836
azathioprine, 837, 838
corticosteroids, 836, 837
FK506, 838, 839
heart, 829–831
IMM 125, 839
immunosuppressive agents, 833–836
kidney, 832, 833
liver, 829
lung, 831, 832
OKT3, 837
polyclonal antisera, 838
rapamycin, 839
Previously transplanted patients, 827–839
anesthetic considerations for, 827–839
infections in, 828
preoperative assessment, 827, 828
Primary platelet plug, 211
Probe. See *Thermometer.*
Prolonged bleeding. See *Desmopressin.*
Propofol, 121, 122, 184, 186, 697
Prostaglandin E_1, 10
Protein kinase, 6
Prothrombin time, 213, 214, 217–219, 228
Proximal sampling, 289–292
Pseudocholinesterase, 700
PT. See *Prothrombin time.*
Pulmonary artery catheter, 309–311
balloon-tipped, 310
benefits, 310, 311
continuous cardiac output, 309
costs, 310, 311
mixed venous oxygen, 309
recent modifications, 309
right ventricular ejection fraction, 309
risks, 310, 311
transvenous pacing, 309, 310
Pulmonary artery catheterization, 334–338
complications, 337
Pulmonary vascular resistance, 808, 809
Pulse oximetry, 311, 312, 326–328
accuracy, 284–286
history, 311, 312
limitations, 312
principle of measurement, 311, 312
sources of error, 312

Rapamycin, 834, 839
Rapifentanil. See *Opioids, new and investigational.*
Recent advances in cardiac pharmacology, **133–168**. See also *Cardiac pharmacology, recent advances.*
Receptor regulation, **1–16**
mechanism of, 4–7
Recipient selection, 679, 680
criteria for, 679, 680
Remifentanil. See *Opioids, new and investigational.*

Renal failure, 679
causes of, 768, 769
in children, 768, 769
pathophysiology of, 694
systemic disorders associated with, 768
Renal transplantation, 691–708
anesthetic technique, 695–705
induction agents, 696–699
inhalational agents, 704, 705
muscle relaxants, 699–703
neuromuscular blocking agents, 703, 704
history of, 691
intraoperative recipient management, 705–708
acidosis, 706
fluid therapy, 706–708
potassium, 706
postanesthesia care, 708
preoperative preparation, 692–695
anemia, 693
coagulation, 693
dialysis, 692, 693
preoperative visit, 693–695
Recipient selection, 691, 692
Repiratory monitoring devices, 266–268
Respiratory distress of the newborn, 288
Respiratory monitoring, advances in, **261–276**
Retinopathy of prematurity, 282
Riley Day syndrome, 485

Santorio, 387
Scopolamine, transdermal administration of, 123–126
Selection of anesthesia monitoring equipment, **357–369**
assessment of available technology, 361–364
determination of needs, 357–360
financial concerns, 364, 365
future developments, 365–367
prioritization of needs, 360, 361
Sequential single-lung transplantation, 749–753, 757–763
Severinghaus electrode, 264, 265
Special considerations for pediatric transplantation, **767–787**
SSEP. See *Evoked potentials, somatosensory.*
SSLT. See *Sequential single-lung transplantation.*
Subclinical myopathy, 514
Succinylcholine, 682, 700, 756
Sufentanil, 699, 733. See also *Nonconventional drug administration in anesthesia.*
intravenous versus intranasal, 21
Systemic vascular resistance, 659, 811

TAH. See *Total artificial heart.*
TCD. See *Transcranial Doppler.*
TEG. See *Thromboelastography.*
Temperature monitoring, 298, 313–315
clinical aspects, 314
sites, 314
axilla, 314
buccal fold, 314
esophagus, 314
nasopharynx, 314
pulmonary artery, 314
rectum, 314
skin, 314
tympanic membrane, 314
Thermometer, 387, 390–398, 400
infrared, 393
liquid crystal, 392, 393
mercury in glass, 390, 391
Thermometry, 331
Thermometry, perioperative, 388–390
hypothermia, intraoperative, inadvertant, 389, 390
intentional, 389
intraoperative hypothermia, 389, 390
Thermoregulation, afferent thermal sensing, 410
central, 410–412
effects of anesthetics, 418–422
efferent responses, 412, 413
nonshivering thermogenesis, 413
sweating, 413
physiology, 409–417
Thermoregulatory research, 401, 402
Thermoscope. See *Thermometer.*
Thiopental, 720
Thiopentone, 696, 697
Thoracic electrical impedance, 315–317
Thoracic organ transplantation, 729–744
history of, 729, 730
Threshold temperatures, 410, 411
Thromboelastography, 213, 223–228, 232
Thyrotoxicosis and thyroid storm, 478–480
Tissue plasminogen activator, 213
To monitor or not monitor, **323–344**
TOF. See *Train-of-four.*
Total artificial heart, 675, 679
Total parenteral nutrition, 813
Train-of-four, 242–247, 252–254
Tranexamic acid, 103–106, 725
adverse effects of, 105, 106
for cardiac surgery, 105
for non-cardiac surgery, 104, 105
nonsurgical applications, 104
pharmacology, 103, 104
Transcranial Doppler monitoring, 187, 188
Transcranial stimulation, 183
Transesophageal echocardiography, 338, 339
Transfusion reactions, acute hemolytic, 482, 483

Transfusion-related acute lung injury, 483
Transplantation, anesthetic management in, 680–686
  bypass period, 683, 684
  immediate postoperative period, 686
  induction period, 680–682
    induction technique, 682
    monitoring, 681
    preoperative sedation, 681
  postbypass period, 684–686
    hemorrhage, 684, 685
    patent foramen ovale, 685, 686
    right ventricular failure, 684
  prebypass period, 682, 683
commercialization, 847–853
  anencephalic infants, 852, 853
  artificial support devices, 851
  compensation to donor family, 848
  fetal tissue, 853
  living donors, 848, 849
  non–heart-beating donors, 851, 852
  xenotransplantation, 850, 851
ethics in, 845–849
Tubocurarine, 255

United Network of Organ Sharing, 673
Uremia. See *Desmopressin.*
Urinary catecholamines, 661

VAD. See *Ventricular assist device.*
Vecuronium, 702
Ventilation monitors, 273, 274
  invasive $PaCO_2$, 274
  noninvasive CO_2, 273, 274
  noninvasive PCO_2, 273
Ventilatory monitoring, 328–330
Ventricular assist device, 674–679, 809
Viscoelastic tests, 222–226
  Sonoclot, 226
  thromboelastograph, 223–226
Vomiting, 119
Von Willebrand's disease. See *Desmopressin, for hemophilia and von Willebrand's disease.*

Wall effect, 271
What affects our ability to monitor?, **345–356**
Wind chill factor, 417
Wunderlich, Carl August, 387